Procainamide Hci
Product Images NDC 51662-1392

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Procainamide Hci (NDC 51662-1392). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51662139226 Procainamide Pouch Label2

Label for PROCAINAMIDE HCl Injection USP, 500 mg/mL in a 2 mL vial. Includes NDC 51662-1392-2, lot number 300930, and expiration date 2030-09-30. Manufactured by HF Acquisition Co., LLC, Mukilteo, WA 98275. The label also contains storage and usage warnings and a QR code at the bottom right corner.*

FDA Label Image

51662139233 Procainamide Case Label

Label for PROCAINAMIDE HCI Injection USP 500 mg/mL in 2 mL vial, box of 25, manufactured by HF Acquisition Co LLC, DBA HealthFirst. The label includes NDC 51662-1392-3, lot number 12345, and expiration date 2030-09-30. It features warnings about metabisulfites and storage instructions, emphasizing aseptic technique and use for intramuscular or intravenous administration after dilution.*

FDA Label Image

51662139233 Procainamide Rfid Label

Label for PROCAINAMIDE HCI distributed by HF Acquisition Co LLC, DBA HealthFirst in Mukilteo, WA. The label includes GS1 data matrix code and listing identifiers (01), (17), (21), (10) with respective values. It notes the user to see the manufacturer's package insert for more information.*

FDA Label Image

Carton Labeling (Box Labeling)

Packaging label for PROCAINAMIDE HYDROCHLORIDE Injection, USP, 500 mg/mL (1 gram/2 mL total) in a 2 mL vial. The label includes usage information, warnings about preservatives and storage conditions, and the manufacturer Hospira, Inc., Lake Forest, IL. The product NDC is 0409-1903-01.*

FDA Label Image

Boxed Warning (Boxed Warning)

A warning text panel about prolonged administration of procainamide, noting it can lead to a positive anti-nuclear antibody (ANA) test and potential lupus erythematosus-like syndrome symptoms, recommending assessment of therapy risks versus benefits if a positive ANA titer develops.*

FDA Label Image

Dosage (Dosage)

A data table showing dilutions and rates for intravenous infusions of Procainamide Hydrochloride Injection, USP. It lists final concentrations, infusion volumes, amounts of procainamide hydrochloride to be added, and infusion rates for initial loading and maintenance infusions. Additional notes provide infusion volume preparation instructions and caution about monitoring flow rates to avoid high plasma levels and hypotension.*

FDA Label Image

How Supplied (How Supplied)

A table presenting units of sale and concentrations for two NDCs: NDC 0409-1902-01 indicates a case containing 25 cartons with a concentration of 100 mg/mL, and NDC 0409-1903-01 indicates a bundle containing 25 cartons with a concentration of 500 mg/mL.*

FDA Label Image

Logo (Logo)

FDA Label Image

Serialized Carton Labeling (Serialized Box)

Box packaging for PROCAINAMIDE HYDROCHLORIDE Injection, USP, multiple-dose vial. The product strength is 1 gram per 2 mL (500 mg/mL). The box shows a volume of 2 mL and contains a warning about metabisulfites. Labeler information includes Hospira, Inc., Lake Forest, IL. The package is Rx only and includes a QR code label.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of procainamide hydrochloride (PROCAINAMIDE HCI) showing its molecular components including an amine group attached to a benzene ring, linked to other functional groups and hydrochloride (HCl). This image represents the active ingredient molecular structure for the product labeled by HF Acquisition Co LLC, DBA HealthFirst.*

FDA Label Image

Principal Display Panel (VIAL LABELING)

Label for PROCAINAMIDE HCl Injection, USP 1 gram per 2 mL (500 mg/mL) multiple-dose vial with 2 mL total volume. The label includes the NDC 0409-1903-01 and identifies Hospira, Inc., Lake Forest, IL as the manufacturer.*

FDA Label Image

Warnings (Warnings)

This text panel summarizes mortality data and safety considerations from the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), highlighting risks associated with encainide and flecainide compared to placebo. It discusses the uncertain applicability to other populations, the proarrhythmic properties of procainamide, and the importance of reserved use for life-threatening ventricular arrhythmias. The panel also details blood dyscrasias linked to procainamide hydrochloride, recommending frequent complete blood counts during therapy and guidelines for discontinuation if hematologic disorders occur.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.